Kulkarni: Welcome to our panel, here. As I said, Iโm Sam Kulkarni, Iโm a partner at McKinsey, and when David and his team said weโre going to do a panel discussion on sitting on a can of miracles, it took me exactly five seconds to say yes. Iโm like, we are living in a world of unprecedented innovationโyes, I want to talk about sitting on a can of miracles. And then, I was already excited, but then I got doubly excited when I heard who the panelists were going to be, and so Iโm very happy to welcome our esteemed panel, here, and I will briefly introduce them, and they will do most of the talking, but I will make sure that they donโt get into a fight, because I see some debates coming about what the miracles really are.
So Iโll start on my left, hereโRyan Bethencourt, as you can tell from his movie, heโs the quintessential entrepreneur and disruptor in the healthcare space. At a very young age, he has started a number of organization. He was a CO and CEO at a biotech companies, but heโs also started Berkeley BioLabs and Indie.Bio, which are new concepts for funding miracles, if you will, or new ideas in the healthcare/biotechnology space. And Ryanโs hoping to really disrupt the space, in terms of how we come up with innovation.
Then we have Amy. Amy DuRoss is a venture capitalist at GE Ventures, and they have a very sizable funded at GE, healthy, you know, healthy imagination, investing in many different, unique, new technology concepts. And Amy has a very unique viewpoint, you know, she was at Navigenics, as one of the, you know, early on in the whole space of genetics and disruption, she was the primary co-author of the stem cell initiative in 2004, that led to a $3 billion dollar funding in the space, to really encourage innovation in the space. And as I was doing my diligence, and Amyโsomeone said, sheโs probably the only English major who sounds like a double-PhD. So weโll hear from Amy.
So then we have Greg. Greg Simon is the CEO of Poliwogg, which is a completely new paradigm in healthcare investing, which isโI wonโt adjust this to it, and Iโll have Greg talk about how you actually get people like us investing in private companiesโ innovation in the future of healthcare, if you will. And Gregโs worn so many different hats, I wonder where you keep them all. He was Chief Domestic Policy Advisor for Al Gore. You were the founding President of Faster Cures, you were at Pfizer, as Senior Vice President of Patient Engagement, and now at Poliwogg.
DuRoss: He was a band leader, too, early on. He was going to be a musician.
Kulkarni: Oh, well lucky for us, he made a good choice, coming to healthcare. And when I did my diligence on Greg, somebody said, โHe should have named his company Poliwonka, because heโs making a lot of things happen.โ
And last, not least, we have Nancy Kelley. Nancy is Senior Executive and lawyerโone of the best lawyers in the healthcare spaceโyou have your own firm, that you tackle a number of different issues across, you know, regenerative medicine, stem cells, personalized medicine. Very intrigued byโyou know, Nancy literally founded the New York Genome Center, raised $110 million to do it, which is a sizable investment into this genomic center. Before that, you were at Alexandria Real Estate, for those keeping track, on of the best-performing stocks of this year, riding on the biotech wave. She was also Whitehouse Fellow and Truman Scholar, and when I did my diligence it said, โDonโt try to make fun of Nancy, because sheโs going to get back at you. You wonโt have a comeback.โ So Iโll stop there.
So, the topic is sitting on a can of miracles, and I think it came from last yearโs discussion, where one of the panelists said, โLook, weโre in an era of unprecedented innovation, we really are sitting on a can of miracles.โ And so what Iโm going to try to get from the panelists what they see are the miracles out there. Is it real this time? And then weโll get into what you need to actually nurture these miracles. And finally, if we get time, weโll have some advice for entrepreneurs out there, from the panelists.
So Ryan, let me start with you. You guys have, through Indie.Bio, funded 12 companies in the last year? Can you talk about what you see as miracles out there?
Bethencourt: Yes, so I can talk about some of the miracles that some of the companies have already started to build. So there is one company that is actually removing the need for cotton or fields of agricultural crops to make biotech cells. They actually made the first thread last weekโso they made out of a vat, they brewed their own biotextiles out of a vat.
Kulkarni: The new silk road.
Bethencourt: Yes, the new silk road, exactly. Making vat-brewed egg whites, so replacing the kind of inhumane, factory farm aspect, and making egg whites that are identical to normal egg whites, in a vat. All the way through to machine vision and robotics, to accelerate kind of the biotech space, something a little more classical. Probiotic therapeutics, that are genetically modified, so protein factories for the developing worlds, where getting the therapeutics is actually really hard, because theyโre proteins and they have to be chilled, and itโs really hard to do that last-mile delivery, or the last 100-mile delivery.
And pretty much a full range, so pretty much everything in the space, starting off at the kind of technical hurdles that weโre facing, and how we scale up to some of the higher-level issues like these.
Kulkarni: And these are entrepreneurs who are not with 25 years of experience. These are entrepreneurs who are starting companies with small innovation funding.
Bethencourt: Yes, weโre very mission-driven, so when people apply to Indie.Bio, they come with a mission, usually a passion. Many of them are young entrepreneurs, but not all of them. Some are actually university professors, some a bio-hackers, some are post-docs who have been stuck in the lab, trying to get out and do something different. And they all have ideas and visions, and with stagnant government financing, many VCs shying away from taking early risk, weโre one of the few actually funding, you know, the first money into, essentially, and idea.
Kulkarni: Yes, speaking of VCs who are not shying away, Amy, can you talk about some of the investments you guys have made, and what you see as really cutting-edge and novel?
DuRoss: Sure, absolutely. So in addition to being a corporate VC with, essentially later, usually later-stage, kind of follow-on approach to the market, we also have a separate group that just focuses on starting new businesses, so wholly independent of GE. GE is usually an investor. Always there is a strategic reason to GE for starting a company. So we just launched our first company, Evidation Health, which is a digital health validation engine that was just launched at South by Southwest, so we see ourselves more as enabling the next generation of miracles. We think there will be some miracles on the digital technology front.
Weโre also spending a lot of time in cell and gene therapies, tissue engineering, the whole regenerative medicine space, which is near and dear to many of our hearts here on the panel. We think that this field, in general, particularly cell and gene therapy, is ripe for industrialization. When you think about how you optimize manufacturing processes, this is mass customization, these autonomous therapies are individual cells then reinjected back into the body. So we think thereโs a lot of opportunity for optimizing the manufacturing of that process and how we take our learnings from jet engine production and apply it across all of the manufacturing components, from the actual patient engagement all the way at the front end of a therapy, all the way down through to dose administration and monitoring for toxicity, and in playing all the sort of Internet of Things technologies, if you will, and the Six Sigma that we have as a company, that sort of competency. So weโre really interested in funding both the point solutions around these technologies, and some of the therapeutics as well, as well as the sort of underlying manufacturing pieces, so.
Kulkarni: Thatโs interesting. You think of GE, you think of airplane engines, you think of, you know, big appliances, and here you are at the cellular level, thinking about regenerative medicine, but itโs very interesting.
So Greg, you have a vantage perspective, as you created your fund, to look at all these different technologies out there, and I think youโve picked, you called it a regenerative medicine fund that youโve created. Can you talk about what youโre seeing, you know, in terms of innovation, and why you picked this particular area to be the fund you create?
Simon: Well, Poliwoggโs mission is to turn health from a cost to an asset. Insurance is a lousy way to pay for your health. Eventually people need to own the factors of production in health, so they can make money from investing in the future of health, which they then use to pay for their own health cost. So in order to do that, you have to verticalize the health sector. Unlike energy and agriculture, which have been verticalized forever, in health, itโs either big-cap pharma or small-cap biotech, but thatโs not how people think about their health. They have Alzheimerโs, or they have a kid with autism, or they have a sister with MS, and yet when they go to invest, thatโs not how the market is organized.
So as an example, when BioGen last week reported interesting results on a drug that may not even be approved for the next seven years in Alzheimerโs, their volume of traded shares went from 1 million to 10 million, and their market cap went up $10 billion dollars. Did all those people invest in BioGen? No. They invested in Alzheimerโs. Why? They donโt know how else to invest in Alzheimerโs. So weโre creating a series of public venture funds, because we think itโs important to democratize access to health investing. Itโs not just for the rich. Thatโs how you build wealth, not just by paying people more, but letting them invest, and weโre creating a series of vertical funds. The first oneโs in regenerative medicines and stem cells, the second oneโs in neurodegenerative diseasesโweโll do them in cardio and metabolic disease and infectious disease, different kinds of cancerโbecause thatโs what people want to invest in.
One statistic that shows you how under-invested people are in healthโthere are $14 trillion dollars invested in mutual funds and exchange-traded funds in America. Of that number, only $180 billion is invested in health. There is more invested in gold. Now that is one of the problems about the can of miracles, is that if weโve gotten all these miracles with the paltry amount of money weโve invested so far, imagine what we could do if we actually let the public start investing in the things they care about, instead of just the VC community, which even if itโs perfect, is only $8 billion dollars, investing in the $3 trillion dollar economy of health.
So we picked regenerative medicine and stem cells for the reason that Jeanne Loring said this morning: weโve been waiting for this for 10 years. Amyโs been incredibly involved in that. And it is now, the dam has burst, and it is happening, and we want people who care about it to be able to invest in it directly.
Kulkarni: Yes, and you know what, when we spoke on the phone, and what he said struck me, which is, the ice bucket challenge, when that happened you saw a spike in investment in ALS, right?
Simon: Right, people focused on the $200 million of donated money. What they didnโt look at, was that all the companies who said they were working on ALS, their stock went up that week. People donโt just want to be donors and spectators, they want to be investors. My father was scared to death of the market. I had a broker and I bought mutual funds. My son is trading options online. The millennials donโt just want to invest through a broker and own a stock, they want to own a company, and thatโs what they should have the chance to do.
Kulkarni: Yes. So Nancy, youโve put large amounts of monies to work in the New York area, in creating these, you know, the infrastructure, I guess, to enable future innovation. Can you talk about the personalized medicine, the Genome Center, what your vision is, and whatโyou also do a lot of synthetic biology, youโre involved in that fieldโwhat are the innovations youโre seeing coming out of it?
Kelley: Yes, so, with the New York Genome Center, I mean really the vision was to bring 11 of the largest academic and medical institutions in the world together. Collectively, they have about 30 million patients going through their doors every year, and by sequencing those patients, and being able to merge that data and then search it to look for variations and patterns, it should lead to the development of new drugs and diagnostics. But even more fundamentally important, New York is the most ethnically diverse population in the world, or it has it, and there are no reference genomes for most of those ethnic population groups, and so by working in the New York area with the people who live in that city, there is the possibility of creating genomic medical approaches that are tailored to ethnic populations, and that it really important because it will allow genomic medicine to come to underserved people for the first time.
Kulkarni: And how does this fit with the Presidentโs initiative around the million people sequenced, and something bigger than what youโre trying to do? Or does that all fit in together?
Kelley: It all fits in together. I mean, at the national level, the precision medicine initiative is really all about obtaining peopleโs unique genetic blueprints so that you can understand what diseases theyโre susceptible to getting. And then once they get them, what medications are going to be effective at treating them, and getting them healthy again? And thatโs what precision medicine means, and itโs what the Presidentโs initiative is all about, and itโs what weโre trying to do in New York City.
Kulkarni: Great. So let me, so letโs come back to whether this is real. So, again, as I was doing my diligence for this panel, I spoke to someone who has been doing biotech for 50 years now, who said, you know, โLast time someone said, โsitting on a can of miracles,โ there was a person who called me about investing in an East Mongolian goldmine this morning, said the same thing.โ And weโve seen this movie play over several times. You knowโand Amy, you saw this Navigenics in 2000, you guys saw this from the policy perspective. Ryan, youโre so young, I donโt know if you saw it, butโ
Bethencourt: Yes, Iโve actually seen it repeatedโwell, the genomics, I did see that. I actually saw the kind of hype and crash.
Kulkarni: Yes, so is it real? Is it real this time, and why?
Simon: Well, if youโevery morning, I get about 10 articles, itโs a bubble, itโs not a bubble. It is not a bubble, for several good reasons. Number one, if you look at the biotech and NASDAQ ramp-up now, compared to what it was in โ99 and 2000, it is nowhere near as steep as it was in the NASDAQ for the dotcom era. In the dotcom era, people were measuring success by eyeballs. In the biotech bubble, weโre measuring success by people who are being cured. The hepatitis C drug, the immunotherapies in leukemia, in stomach cancer and lunch cancerโso thereโs no comparing somebodyโs page views versus people getting cured.
The other thing about biotech is that products are not substitutable. If you have a pet food dotcom, and there were 60 of them in the dotcom bust, theyโre all substitutable for each other. If you have the new hep C drug, it is not easily substituted by anything else. So biotech, unlike tech-tech, is not a question of somebody elseโs garage has a better app six months from now. We know, because itโs all public, what the pipelines are at the FDA, and when there are a whole series of drugs and products in development for certain diseases, when those hit, they are valuable, regardless of what else is going on.
And just like oil used to be a problem when the cost went up, and now itโs a problem when the cost goes downโhave you wondered why that is? Itโs because oil used to just be a cost, and now itโs an asset. When health becomes an asset, the money we spend on health going up will not be a problem, because everybody will be owning the factors of production and the products that are curing them, rather than just thinking of themselves as insurance victims, and it will make a huge difference. This is not at all like the dotcom bubble, which I definitely went through.
Kulkarni: Well, Amy, let me ask you this, since you were so close to the stem cell regeneration. I think in 2000 or 2001, with Geron, we saw videos of miceโor this morning, I donโt know if people saw the video of mice whose spines were crushed, and then they were running aroundโI donโt know who showed the video, but we saw that 10 years ago, right, and then what happened? It did not work. So why is this time do we have better understanding?
DuRoss: There was essentially a Valley of Death in the fundingโit gets back to the funding. That became an issue. Geron lost its funding. They have now actually recouped some of the funds, and there is a version of that trail is moving forward, albeit slowly, more slowly than it should have, from its initiation, but I think itโs largely a funding challenge. I mean, we at GE, weโre so focused on the enabling technologies, weโre not a therapeutic company, but you see just even within the genomic revolution that the actual advances in the technology are in excess of Mooreโs Law.
And so we have just continued to accumulate these masses of data, and so now weโre actually able to mine that data more carefully, itโs jut that, you know, we havenโt had the funding on the discovery side, and sort of the continuity of funding hasnโt always been there in the last decade. You know, NIH budgets have shrunk, we donโt have other instruments until, you know, Polliwogg and others have come along to really try to democratize the funding and smooth out the lumps. I mean, I think thatโs really the underlying problem, as far as I can see.
Kulkarni: So itโs the funding, and now thereโs better funding, so weโre seeing this real uptake. But is there something in the science? Is there something thatโs changed? Nancy, do youโฆ?
Kelley: Yes, I was going to say that I think in addition to that, that weโre seeing the return of a huge investment in a technological foundation for understanding the way that life unfolds, that, you know, we hadnโt seen before. We didnโt have the benefit. So it started in 2003, with the sequencing of the first human genome, and then since then, as the speed and cost of not only sequencing, but synthesizing, DNA has come down, youโve seen not only, you know, the opening for precision medicine to enter the marketplace, but also synthetic biology. You know, a whole new area of science with applications that are far beyond the healthcare boundaries.
Kulkarni: Yes, Ryan do you agree?
Bethencourt: Yes, I totally agree. I mean, this is the biology of everything now, right? Steering away fromโand weโve heard from some earlier panelists and some earlier talksโweโre steering away from just biomedical applications of biotech, to everything. So as an example, one of the companies weโve invested in, Arcturus BioCloud. They will enable consumers to get bio-bricks, and kind of like iGEM.
Kulkarni: Sorry, what are bio-bricks?
Bethencourt: So bio-bricks are pieces of DNA that code for a particular protein or an enzyme, it does something, right? So kind of like Legos, but for biology, you can start putting them together, right? And you can actually do this in the cloud, cloud-based science, right? And you can actually start making things. So theyโve already started theirโthe beta testing, right? So this is real, like, this is real, like, right now. You know, right? And so these are the types of things that weโre going to start to see.
Weโre using, Pembient is using synthetic rhino horn to combat poaching, right? So weโre looking at, like, how do we look at the world as it is, and how do we change it for the better? How do we feed people? How do we provide clean water or new bio-materials? And then eventually, like, how do we heal them?
Kulkarni: Yes, Yes. So Ryan, youโre trying to create thisโyou called the Valley of Death, and how you get across itโthereโs the early funding, because people have ideas, whether you want to grow a plant thatโs glowing or something else, that we heard in the previous panel, and itโs the early one to two million dollar funding. But let me challenge, which isโwhat Gregโs saying is, weโre not talking millions of dollars here, weโre talking, you knowโthereโs only $180 billion dollars, whereas it should be a trillion dollars or two trillion dollars in this market. How is your bottom-up way of trying to get across this chasm, if you will, mini-chasms? How is that going to solve the problem?
Bethencourt: Because weโre no longer stuck in the box of biomedical innovation, right? So itโsโso biomedical innovation has a box, and there are certain VCs that are typically risk-averse, and they cut checks, and their check sizes are five to twenty million dollars. If you canโt get to five, you canโt get to that point where theyโll invest, typically a phase IB, IIโII, typically. In clinical testing, youโre not going to get funded, right? And usually youโre low-risk, right? Usually your drug thatโs been proven, you know how the mechanism works, and then itโs easy for a big firm to cut a checkโand there are a bunch of them in Silicon Valley that cut big checks, they have billion-dollar funds, usually billion-dollar-plus funds.
Weโre doing other things. Weโre actually going direct to consumer, weโre selling to consumers. Weโre innovating in spaces where other people donโt, so weโre bringing the tools of molecular biology into spaces that typically wouldnโt use them.
Kulkarni: I donโt know if you have too much competition in rhino horns, but it does sound like you found some niches.
Bethencourt: Yes, and itโs controversial, right? Itโs controversial, but what if it works, right? Then could we use that model in other areas too, right? Iโm a vegan, right? Why isnโt there in vitro meat? And these are questions that we can answer with biology.
Kulkarni: Yes. So, Amy, your take, from a VC perspective on this?
DuRoss: Yes, I think not so much in the sort of regenerative medicine space, but certainly on the digital technology side, some of these valuations are so stratospheric that, you know, typically corporate VCs play later, and itโs justโthe returns analysis are just very difficult, when you think about going inโwe just saw a company that came in the other day, they have a great service, a very disrupting service, theyโre disintermediating pairs, all the things we love. But you know, their valuation is $800 million dollars on $3 million in revenue, you know? And they said it with a straight face, and they said that another hedge fund gave them an over-billion dollar valuation and they rejected it. So you know, this is the kind ofโyou see this really on a weekly basis in our shop, so itโs very hard. Youโre either going to play very early, and to your point, youโre going to do sort of dribs and drabs of funding at very high risk, or youโre going to go in on the B, C, you know, even D stage, and itโs very difficult to make a returns analysis work out.
So you know, I think weโre all waiting for the crash. Itโs going to come. And the pundits tell us, you know, when then think, depending on whom they are, and I think thatโsโI think we need a correction, because it does make it very difficult, in the absence of many other instruments or approaches to funding, it makes it difficult as a venture funder to find that sweet spot, where your status, especially as a corporate VC, where you have these other kind of constraints from the street, that you can really make an analysis work.
Kulkarni: But Greg, you donโt think thereโs going to be a crash. You think this is real, right?
Simon: Well, I think the biotech is real. Digital health does not always go together. A lot of things are digital, but have nothing to do with health. Iโm sorry. Wearing your Fitbit at Dunkinโ Donuts is not a digital health product, you know? So what Iโmโmy plea to the Valley is stop trying to make us live 200 years, and help us live at home until we die. Think about it. Would you rather live 200 years, or would you rather just be able to spend the last days of your life at home, instead of in a facility or a nursing home, and all the things that the boomers have seen their parents do, which we refuse to want to do.
And so to do that, to stay at home, weโre going to have to invest in things that make the quality of life better. And for that there is no bubble, because the boomers are the most selfish generation in historyโweโre turning 65, 10,000 a day for the next 18 years, and the millennials are turning 35 10,000 a day for the next 18 years, which is going to create an enormous bull market, because theyโre coming into the equity-buying age. And the point being is, if youโre in the investment business, and youโre looking at the demise of energy, and youโre looking at the demise of the EU and Greece and all of that, where are you better going to invest in here, and what sector is more interesting and more exciting than health?
So I think the digital health thing has gotten a lot of hype, and Bruce Booth at Atlas Venture has written a tremendous series of blogs, one of which pointed out that in the digital space, thereโs tons of money for the beginning of a lot of companies, but thereโs not a lot of money for the end-stage buy-out. In biotech, thereโs a ton of moneyโwe call it pharmaโfor the buy-out, but thereโs not been a growing piece of capital for the start-up. Why? Because we donโt have the capital market tools to allow the average investor to invest in a diversified portfolio of early-stage companies. So a year ago, Poliwogg started an index to measure 75 companies with a drug in a stage 2 or 3 trial, under $5 billion market cap, with two years of cash. It became an ETFโand exchange traded fundโon New Yearโs Eve. Itโs up 20% this year, itโs added $5 million of assets every week, with no marketing, no sales, and no PR. Why? Because retail investorsโmany of them couldnโt even buy it through their bank until it hit $25 millionโwanted to invest in small companies, and all the other ETFs are just another way to buy Pfizer. All the other ETFs are dominated by the top ten big pharma companies.
So you give people an opportunity to invest in the future, they will take it. But what Poliwogg, you know, JP Morganโwho would you expect to do this? It should have been JP Morgan, but itโs Poliwogg. Sooner or later, it will be JP Morganโs idea.
Bethencourt: Yes, Yes. Itโs really important not to forget though, that weโre not talking about just the US, right? I mean, weโre talking about seven billion people on this planet, most of whom donโt have enough food. Like, most of whom, GMO technologies are really important. Thatโs how they eat, right? In India, like, they celebrate the original genetic modification pioneers, right? Whether itโs traits or other things, so itโs like, thereโs a huge global market. There may be 300 million in the US, maybe another 500, 600 million in Western Europeโthatโs not even a majority.
Kulkarni: Itโs interesting you bring that up, Ryan, because there was a panel earlier this morning on food and beverage that I thinkโwas it Jim who mentioned, which is, you know, you do the Tesla model, where you try to solve the problems of the US and itโll flow down, but if you try to create a completely different solution, it may not always be adopted. And thatโs a differentโgood point, but itโs a different debate to have.
Bethencourt: We donโt view it that way. And we view it like, if you canโtโif the financial markets wonโt work, right, you find a way. Many of us are bio-hackers, right? Weโll find a way to do it, and weโll make the technology available, right? Whether itโs open source, or whether weโll just sell it for pennies, right? Maybe those pennies matter.
Kulkarni: So getting away from funding for a little bit, and kind of going back to scienceโNancy, when we spoke, you said, โYes, the can of miracles, thereโs a lot of things here. Thereโs synthetic biology, epigenetics, thereโs gene editing, there is, you knowโโI canโt even say all the things that you mentioned. But let me do a rapid-fire round here for the panelโif you had to invest in one of these technologies, only one, you can only pick one, whether itโs personalized medicine, synthetic biology, regenerative medicine, gene editingโI know theyโre all related, but pick oneโand then youโve got to have a bold prediction for what the technology is going to do 10 years from now. Who wants to start? Do you want to start?
Kelley: I would say engineering biology, rather than synthetic biology, because itโs a broader category. And I think that itโs going to introduce solutions to many of the global problems that weโre facing in agriculture, energy, health, environment, etcetera.
Kulkarni: Which explains the valuation of Intrexon and some of the companies like that, right? So engineering biology, okay. Greg?
Simon: I would go with neuroscience, because if we donโt solve the Alzheimerโs problem, every hospital in the country is going to be filled with Alzheimerโs patients in 20 years. We have gotโwhen President Obama proposesโand Iโm a Yellow Dog Democratโwhen he proposed $60 billion dollars to subsidize community colleges with lousy graduation rates, and $100 million for Alzheimerโs research? Please.
I mean, the biggest threat to the country right now is Alzheimerโs and dementia, and if we donโt throw tons of money at that, weโre not going to solve it. You heard Casey this morningโI get ten articles a day about what people are doing in new trials for Alzheimerโs. We can do it. Most people will argue that we canโt do it, we can do it. But not at $100 million dollars from the government. It has to reach a huge scale. And the brain is the most difficult thing to figure out, on purpose. Your brain is designed not to let people go in there and reprogram it. So if you have a brain problem, it, by definition, is the most difficult problem. Thatโs what I think is the most exciting stuff.
DuRoss: Are you asking as an investor, or as a sort ofโ
Kulkarni: No, you could be an entrepreneur, wanted to make a bed, develop something in the space, not just an investor. Could be investor.
DuRoss: Well, itโs really expensive, but I think autologous cell and gene therapy is where itโs at, because itโs justโthe data coming out of these phase III, and there are a couple phase IV trials overseas, are justโitโs curative. And I thinkโ
Kulkarni: Yes, and just to explain to the audience, what autologousโ
DuRoss: Yes, this is for the, essentially the T-cell therapyโitโs basically you take a personโs own cell and you reprogram it to then go back inside the body, the patientโs own bodyโthereโs no autoimmune rejectionโand attack tumors or tumor cells. So itโs pretty amazing, and itโs been in development for 30 years, itโs not a new concept. But weโve just finally got the point where the technology has really actually supported the thinking around it. Soโand weโre curing cancer in these trials. Carl June at the University of Pennsylvaniaโitโs phenomenal, what the data is telling us. So, thatโs why our company is making such an interested investment, and weโre trying to really enable the underlying manufacturing technologies, because right now theyโre producing these therapies in tens and twenties, because these are the sizes of the trials, more or less, and how do you get, when youโre sort of ready, get through approval, how do you kind of push go and make sure that youโre taking care of millions of cancer patients out there? So.
Kulkarni: Yes, you know, for those in the audience who have not kept up with the autologous T-cell space, this is mind-boggling, and I sawโwent and saw a patient in a clinic, which is, you take a personโs immune system or cells, reengineer it, put it back into the personโs bodyโor, you know, thereโs different ways to do itโthe person who has cancer canโt move, and you know, has all sorts of sequelae, all of a sudden gets this fever, it feels like oh my god, this personโs going to die, this sweating fever, 48 hours, then the cancer is eaten up. This is veryโyou know, this is quite mindboggling when I saw it in real life versus reading it in papers, and I can definitely see how this could be quite earthshaking.
DuRoss: Transformative.
Kulkarni: Yes. Ryan?
Bethencourt: Mine is nuanced. So vascularization, thatโs where I would invest, and thatโs where I would like to see progress, like, actual vascularization. So what I mean by thatโand itโs really important to clarify what I mean by thatโis I mean the ability to grow capillaries and blood vessels within tissue, right? And this is actually one of the biggest stumbling blocks for organogenesis, printing, creating new organsโitโs one of the biggest stumbling blocks we have for in vitro meats. Itโs like, itโs a really important key that everyone is waiting for, right? Iโm sure GEโ
DuRoss: Yes, absolutely.
Bethencourt: Similar kind of issue, right? Like, once you can vascularize tissue, then you can start to imagine what you can do with these tissues. Once you can grow tissue, you can grow mammalian tissue, fish, you know, every species of tissue, and you can start to do really unusual things with it, like growing organs, or maybe growing new biomaterials.
DuRoss: I think Nina Tandon is speaking later today.
Bethencourt: Yes, there we go. Thatโs goodโ
DuRoss: She gets to tell you more about vascularization, but it is being the sort of missing link when you have phenomenal structures that are being engineered in tissues, tissues from hollow structures, all the way to organoids and full organs, like kidneys, that have been in patients for five years, fully functioning. Itโs remarkable whatโs possible, but again, if you get to the mass customization problem, again, itโs how do you actually keep these tissues living once theyโre ex vivo, before theyโre transplanted, and it is a real stumbling block before we can industrialize.
Kulkarni: And Ryan, just for the audience, is this like growing, you know, heart tissue? Is this like growing retinal tissue?
Bethencourt: This is growing everything. So, everything from Modern Meadows leather, right, which is dependent on vascularization to grow thicker tissues, all the way through to growing tissues to replace burn victimsโ skin cells, through to replacing hearts, and then replacing animals in the food chain.
Kulkarni: So if Poliwogg comes up with an ETF called vascularizationโฆ?
Bethencourt: Iโm on it, Iโm totally investing.
Kulkarni: Youโre running it, youโre not investing.
Bethencourt: Okay, Iโm running it. That sounds good.
Kulkarni: Weโll open it up to the audience in a second here, but one thing I wanted to cover, since we had all the policy experts here as wellโagain, rapid-fire, if you had the power to change any policy you could today, to enable innovation, one policyโpick that, and what would you change? Start with you, Ryan.
Bethencourt: I would make all FDA testing voluntary. FDA testing regulations voluntary. And the reason I say that, is I think that weโve become too risk averse when it comes to testing new therapies, and I think that educated people should be allowed to take risks. Iโve worked with people who have died of ALSโone of my last companies was Halpin Neurosciences, my investor died of ALS. He couldnโt get access to drugs, experimental drugs, and so Iโd push for that.
Kulkarni: Yes, another example this morning of someone who went to Tijuana and got stem cell therapy, right, and it worked. Amy, what would you change?
DuRoss: You know, I think the reimbursement problem continues to be such a bugaboo, and if you could actually kind of use health economics and think about cost avoidance, when youโre thinking about whatโs the overall kind ofโwhat should the reimbursement rate for some of these really transformative, curative technologies, like autologous cell and gene therapiesโI think thatโs a fundamental kind of disconnect. You know, we have lots of disconnects in the healthcare system. Our incentivization is all misaligned, thereโs a lot of problems. But if you could just think, okay, what are we actuallyโfrom the patientโs point of view, how are we helping this patient, both in terms, of course, of first their quality of life and their longevity, but how are we also helping them and everybody who supports their care, including payers and employers, and all the people who are investedโtheir providersโhow to we actually think about the total equation, and whatโand then translate back toโ
Kulkarni: Iโm sure Greg will disagree with that, because that makes it a cost.
DuRoss: [LAUGHTER] Not an asset, right.
Simon: I would eliminate any regulation that uses wealth as a proxy for wisdomโand the good news is, itโs already be done. Congress passed the Jobs Act in 2012, the SEC, scared to death by consumer groups who donโt want people to invest their own money their own way, is telling people that the average investor isnโt smart enough to know how to invest their money, donโt let them. They can buy lottery tickets, $83 billion a year, they can be parents. They can drive. They can buy a gun. But they canโt invest in a start-up company if theyโre not wealthy. That needs to get changed, Congress changed it, the SEC has refused to implement the regulations.
Why? I mean, this is nuts. Because the problem is letting people invest in what they care about, not just donate. Donations are great. I ran an organization around the growth of donations, but people want to invest where they donate. They donโt just want to be a spectator.
Kulkarni: Yes, good. Nancy?
Kelley: I think that I would change the way that we fund basic and applied research in the government. You know, I think David said earlier this morning that last year I was here and I gave an alarmist presentation. I actually think it was more cautionary. But the truth of the matter is that we actually donโt have a rational way for the United States government to identify important trends that are occurring in science and then, in an interagency basis, to be able to evaluate and target investment in ways that will advance that sector year over year over year and allow us to measure the return on that. And until thatโs done, we are in danger of falling behind, because other countries are applying that methodology.
Kulkarni: Yes, great. Thank you. Weโll open up to the audience. Any questions? Is thereโgo ahead, is there a microphone? Right in front.
Audience1: So, great panel. I mean, excellent point of views, and a divergence and convergence of them, so thank you so much. Youโve, you know, your comment on vascularization sort of preceded my question. 3D organs, I mean, we know that thereโs a huge need in the world, and yes, we lag behind because of what Nancy saidโthe inability of the government to create programs to identify where the state of the art is, and how can we fit into that economic and market intelligence, right? And public health issues. And so can you go back and talk about why we havenโt looked into this in the past, and promote these 3D organs much moreโand whatโs your estimate? When are weโ
Bethencourt: So we haveโand Iโll start offโI know, GE, by the way, GE is a huge proponent of stem cells and eventually a path that goes down to it, which is organogenesis, so 3D-printed organs or grown organs. But we have looked into itโso I was at the X Prize Foundation, I looked deeply into organogenesis.
There are many researchers right now working on that challenge, globally. Theโagain, the same stumbling block keeps coming up, like, vascularization, right? So there are other issues, right? Do we really know, the stem cellsโwhen we look at a stem cell, do we really know what that stem cell actually is? How do I identify that? Is that really the fifth type of kidney cell, or not? Right? Identifying is really difficult, so we have to improve in our ability to understand the core, the basic science behind building organs. And it sounds like you had aโ
Audience1: Are you talking about a lack of appropriate bio-inks and also scaffolds? I mean, those are two other areas of thisโ
Bethencourt: All of the above. All of the above, because to meโso even growing on a scaffold, rightโso letโs say today, right? There are researchers at Harvard, George Church and others, who have grown hearts, right? Theyโve actually revascularizedโyou basically take a scaffold, you strip it of cells, you revascularize, you put heart cells, human heart cells, and you pump blood through it. What happens? It bleeds. It just goes pssshโthe capillaries donโt stand up to the pressure. Thereโs something that we donโt quite understand, some groups have claimed that theyโve been able to get better and better at it, but weโre stillโthis is, we donโt know whatโs going wrong. Like, weโre trying to fix it. There are very, very smart people that have spentโone researcher over at Yale, Laura, she spent 20 years trying to answer this question. So if we could have more concerted focus and investment in this area, I think that we could do incredible things, and then what happens next, right? Once you can start replacing failing organs, then you start tackling all sorts of diseases, and maybe you will get, you know, to live 120 or 200 years, because youโre not going to die of heart failure, youโre not going to die of kidney failure, right? In the U.S. alone, like, people are dying all the time because theyโre on dialysis, and so theyโre on a slow train to death.
Kulkarni: That will definitely bankrupt Medicare. Why donโt we doโis there another question from the audience?
DuRoss: I would just say, on the tissue engineering side, the discovery has been so siloed today, at least in this country, there have been some, thereโs better collaboration overseas in some pockets, but Tony Atala, whoโs down at Wake Forest, for example, has a big initiative that is really kind of federating all of these various academic centers of excellence and starting to share data and best practices and different methodologies around trying to really solve the gaps, particularly around vascularization. But I think, you know, itโs just, itโs a very complex problem, and weโve sort of got it figured out on the hollow structures, you know, urinary conduits, some of these very early kind of installations, but as you move down the spectrum of complexity and you get to full, you know, organoid or full organ replacement, itโs been done with a kidneyโas Iโm sure youโre awareโbut itโs just so highly complex, we just have, I think, unfortunately a long road to go.
Bethencourt: All these structures are so exquisitely complexโitโs the most complicated machinery on this planet, right? Thereโs nothing more complicated, like, technology makes the technology AI look simple, right?
Kulkarni: Another question out there?
Audience2: Yes, hi. Greg, your hypothesis that the average person cannot invest in the early stage or in biotechโcould you talk more about it? Itโs a fascinating hypothesis. You mentioned how there are some roadblocks with the SEC, some obstaclesโhow could it go forward?
Simon: So, since 1974, you had to have the net worth of $1 million dollars, or an average salary of $200,000 a year, to invest in a private company. Worse, the First Amendment didnโt apply to youโif you were raising money for a private company, you couldnโtโbefore 2013, when the regulation, this part was done, if I stood on the stage and said that Poliwogg was a private company raising money, and here is its term sheet, Iโd go to jail, right? Now I could talk about the seven deadly sins, and I could say awful things about the President, but if I said, โI want you to invest in a private company,โ and I didnโt know that you were wealthy, Iโd go to jail.
So that has changed, so that I can now advertise a private company as raising money to the world, but only people who have a million dollars in net assets are allowed to invest, even today. So the Jobs Act that passed in 2012 said, we need to let everybody invest, and initially weโll cap it at a certain percentage of their income, if theyโre under $200,000, and you canโa company can only raise a million dollars. Which is a ridiculous limit put on there by the consumer groups.
So, why is that ridiculous? Wealth inequality is about who can invest and who cannot. Since โ74, when only the wealthy could invest in private companies, the wealthy have acquired $35 trillion dollars of wealth, and everybody else has acquired $15 billion dollars of debt, because they couldnโt invest to build wealth. They had to borrow money to get a new car, a better college, or a better house. So now, we need to start letting everybody invest, and the argument that people are too stupid, they canโt afford, etcetera, etcetera, is ridiculous, when you consider that it is the government that promotes lotteries. The government that promotes lotteries, and they never tell you, by the way, your chance of getting anything is a snowball in hell. On the New York subway, it doesnโt say, โBuy the New York lottery ticket: here are the risks.โ But when I put out a prospectus, 90% of it is: hereโs the risk if you invest.
This is upside-down. This is completely upside-down. People need to be able to put their money where their interests are, and yes, some people will lose their money, but the wealthy have done very, very well by being able to invest in private companies that nobody else could invest in. If you can buy Facebook at $38 at the IPO, why canโt you buy it at a dollar, when itโs an early-stage company. The public ends up giving the wealthy $38 a share for something they paid a buck for, that the public couldnโt buy. This is why the wealthy are wealthy. NoโI donโt blame them, you know, but why shouldnโt the public be able to buy Facebook at a dollar?
Kulkarni: So I think weโre out of time, but you know, I want to thank the panelists here. You know, I hope that weโre sitting here next year saying, gosh, the miracles are happening, you know, the funding challenges have been solved, the policy challenge have been solved, but time will tell.